Quest Diagnostics Inc vs Prudential Financial Inc — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while Prudential Financial Inc trades at $122.19 (market cap $42.20B). The key difference: Prudential Financial Inc is the larger of the two by market cap, and Prudential Financial Inc pays the higher dividend (4.58%). Which is the better fit depends on your goals.
| DGX | PRU | |
|---|---|---|
Market Cap | $26.21B | $42.20B |
Sector | Health | Financials |
52-Week High | $238.50 | $123.93 |
52-Week Low | $173.49 | $92.00 |
Enterprise Value | $31.97B | $70.98B |
Dividend Yield | 1.45% | 4.58% |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.
The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.
Prudential Financial (PRU) trades at $122.63, up 0.43% on the day, with a bullish technical signal from moving averages and recent earnings beats in Q1 and Q2 2026. The company reported Q2 EPS of $4.08, exceeding expectations, driven by strength in PGIM and international segments. Valuation remains attractive with a P/E of 11.09 and P/S of 0.66, while a $1.40 quarterly dividend supports income appeal.
Outlook is cautiously optimistic given earnings momentum and strategic focus on capital-light operations, but risks include sensitivity to interest rates and regulatory changes in key markets like China. Analyst consensus is mixed with a Hold rating predominating, though institutional holdings show increased interest, suggesting potential for upside if execution continues.
Trailing returns across standard periods
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Prudential Financial is a large, diversified insurance company offering annuities, life insurance, retirement plan services, and asset management products. While it operates in a number of countries, the vast majority of revenue is generated in the United States and Japan. The company's investment management business, PGIM, contributes approximately 15% of its earnings and has over $1.5 trillion in assets under management. The U.S. businesses are responsible for about 45% of earnings and can be classified into Institutional Retirement Strategies, Individual Retirement Strategies, Group Insurance, Individual Life Insurance, and Assurance IQ. Finally, the international business segment of the company contributes approximately 40% of earnings with a strong market position in Japan.
Read more on PRU →